U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
Aug 22, 2022
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received GAITHERSBURG, Md., Aug. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced tha